Related Experiment Video

Updated: Jun 22, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Minimal hepatic encephalopathy

Radha K Dhiman1, Yogesh K Chawla

  • 1Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. rkpsdhiman@hotmail.com

Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology
|June 17, 2009
PubMed

Insights

Minimal hepatic encephalopathy (MHE) is a subtle liver condition causing cognitive issues in cirrhosis patients. Early screening and ammonia-lowering treatments like lactulose can improve outcomes.

Area of Science:

  • Hepatology
  • Neurology
  • Clinical Medicine

Background:

  • Minimal hepatic encephalopathy (MHE) represents the earliest stage of hepatic encephalopathy (HE) in patients with liver cirrhosis.
  • MHE presents with subclinical cognitive and psychomotor deficits, affecting 30-84% of cirrhosis patients, particularly those with impaired liver function.
  • It is linked to reduced quality of life, progression to overt HE, and poorer survival rates.

Purpose of the Study:

  • To review the characteristics, diagnosis, and management of Minimal Hepatic Encephalopathy (MHE).
  • To emphasize the importance of screening for MHE in patients with liver cirrhosis.
  • To discuss the role of ammonia in MHE pathogenesis and the efficacy of ammonia-lowering agents.

Main Methods:

  • Review of existing literature on Minimal Hepatic Encephalopathy (MHE).
  • Discussion of diagnostic challenges and proposed criteria for MHE.
  • Analysis of the role of ammonia and the effectiveness of treatments like lactulose and probiotics.

Main Results:

  • MHE is characterized by mild cognitive and psychomotor impairments, often undetected without specific testing.
  • Standardized diagnostic criteria for MHE are still lacking, relying on clinical assessment and neurophysiological tests.
  • Ammonia is implicated in MHE pathogenesis, similar to overt HE.

Conclusions:

  • Screening all cirrhosis patients for MHE is recommended due to its significant impact on quality of life and prognosis.
  • Ammonia-lowering agents, including lactulose and probiotics, show promise in improving MHE symptoms and possess a favorable safety profile.
  • Further research is needed to explore the potential of other agents like rifaximin, acetyl L-carnitine, and L-ornithine L-aspartate.

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...